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Abstract
Background:  Production of interferon (IFN)-γ is key to efficient anti-tumor immunity. The
present study was set out to investigate effects of IFNγ on the release of the potent pro-angiogenic
mediator IL-8 by human A549 lung carcinoma cells.
Methods:  A549 cells were cultured and stimulated with interleukin (IL)-1β alone or in
combination with IFNγ. IL-8 production by these cells was analyzed with enzyme linked immuno
sorbent assay (ELISA). mRNA-expression was analyzed by real-time PCR and RNase protection
assay (RPA), respectively. Expression of inhibitor-κ Bα, cellular IL-8, and cyclooxygenase-2 was
analyzed by Western blot analysis.
Results: Here we demonstrate that IFNγ efficiently reduced IL-8 secretion under the influence of
IL-1β. Surprisingly, real-time PCR analysis and RPA revealed that the inhibitory effect of IFNγ on
IL-8 was not associated with significant changes in mRNA levels. These observations concurred
with lack of a modulatory activity of IFNγ on IL-1β-induced NF-κB activation as assessed by cellular
IκB levels. Moreover, analysis of intracellular IL-8 suggests that IFNγ modulated IL-8 secretion by
action on the posttranslational level. In contrast to IL-8, IL-1β-induced cyclooxygenase-2
expression and release of IL-6 were not affected by IFNγ indicating that modulation of IL-1β action
by this cytokine displays specificity.
Conclusion: Data presented herein agree with an angiostatic role of IFNγ as seen in rodent
models of solid tumors and suggest that increasing T helper type 1 (Th1)-like functions in lung
cancer patients e.g. by local delivery of IFNγ may mediate therapeutic benefit via mechanisms that
potentially include modulation of pro-angiogenic IL-8.
Background
Interleukin (IL)-1β is a cytokine with a key role in the
pathophysiology of local and systemic inflammation [1].
Moreover, owing to its pro-inflammatory nature, IL-1β is
regarded a tumor-promoting cytokine. In fact, enhanced
tumor metastasis and angiogenesis has been observed
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under the influence of IL-1β [2,3]. Accordingly, IL-1β is
able to facilitate tumor progression in murine models of
lung cancer. Upregulation of metastasis and tumor angio-
genesis by IL-1β as observed in those studies was associ-
ated with increased activity of matrix metalloproteinases
and expression of the pro-angiogenic molecule hepato-
cyte growth factor. Furthermore, blockage of the chemok-
ine receptor CXCR2 inhibited tumor growth in vivo
indicating that a functional murine IL-8 homologue con-
tributes to IL-1β-mediated progression of disease [4,5].
Notably, the chemokine IL-8 (CXCL-8) is an efficient
mediator of angiogenesis [6,7] and thus located at the cru-
cial interface of inflammation and tumor biology. Neu-
tralization of IL-8 reduced tumorigenesis of human non-
small cell lung cancer (NSCLC) in the SCID mouse model
[8]. A key role for IL-1β-inducible IL-8 in the progression
of lung cancer is strongly suggested by various clinical
studies demonstrating that IL-8 detected in patient biopsy
specimens positively correlates with tumor angiogenesis
and metastasis. Moreover, IL-8 is associated with short-
ened survival, particularly in NSCLC [9-12]. Cell culture
data suggest that lung carcinoma cells are a highly relevant
source of IL-8 in the tumor microenvironment [9,13].
Interestingly, a recent study also demonstrates that IL-8
mediates proliferation of the human NSCLC cell lines
A549 and NCI-H292, respectively [14]. Those observa-
tions further underscore that IL-8 can be regarded a piv-
otal factor in the progression of lung cancer.
Bulk of data from preclinical research indicates that inter-
feron (IFN)-γ mediates important tumor-suppressive
functions. Those include supression of proliferation and
angiogenesis, induction of apoptosis, and activation of
leukocytes with anti-cancer activity such as NK cells, NKT
cells and T cells [15]. Interestingly, inhaled IFNγ showed
therapeutic efficacy in a murine model of lung cancer
[16]. Moreover, application of IFNγ by aerosol is able to
activate alveolar macrophages in human beings [17] and
shows therapeutic potential in tuberculosis patients
[18,19]. In order to further characterize IL-8 as an immu-
nopharmacological target, we set out to investigate in the
present study effects of the tumorsuppressive Th1-like
cytokine IFN-γ on the production of IL-8 by NSCLC A549
cells under the influence of IL-1β.
Methods
Cell Culture
Human A549 lung carcinoma/epithelial cells were
obtained from the German Collection of Microorganisms
and Cell Cultures (Braunschweig, Germany). Cells were
maintained in RPMI 1640 supplemented with 10 mM
HEPES, 100 U/ml penicillin, 100 μg/ml streptomycin,
and 10% heat-inactivated FCS (GIBCO-BRL, Eggenstein,
Germany). For the experiments, confluent cells on poly-
styrene plates (Greiner, Frickenhausen, Germany) were
washed with PBS and incubated in the aforementioned
medium. Human IFNγ was obtained from TEBU/Pepro-
tech (Frankfurt, Germany) and IL-1β from Invitrogen/Bio-
source (Karlsruhe, Germany).
Detection of IL-8 and IL-6 by enzyme-linked 
immunosorbent assay (ELISA)
Levels of IL-8 and IL-6 in cell-free culture supernatants
were determined by ELISA according to the manufac-
turer's instructions (BD Bioscience/Pharmingen, Heidel-
berg, Germany). Two splice variants of IL-8 with different
C-terminal regions can be discriminated (database Swiss-
Prot/TrEMBL, http://www.expasy.org/cgi-bin/get-all-var
splic.pl?P10145). According to information provided by
the manufacturer both splice variants of IL-8 are being
detected by the ELISA assay used in the current study. In
addition, various N-terminal IL-8 variants that are being
generated by proteolytic cleavage are recognized by the
assay.
Analysis of IL-8 and glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) mRNA expression by real-time 
polymerase chain reaction (PCR) analysis, standard PCR 
analysis and RNase protection assay (RPA)
After RNA isolation (peqGold TriFast, Peqlab, Erlangen,
Germany), 1 μg of total RNA was transcribed using ran-
dom hexameric primers and Moloney virus reverse tran-
scriptase (RT) (Applied Biosystems, Darmstadt,
Germany). During real-time PCR analysis changes in flu-
orescence are caused by the Taq-polymerase degrading the
probe that contains a fluorescent dye (FAM used for IL-8,
VIC used for GAPDH) and a quencher (TAMRA). For IL-8
(Hs00174103_m1) and GAPDH (4310884E) pre-devel-
oped assay reagents were obtained from Applied Biosys-
tems. Assay-mix was purchased from Invitrogen
(Karlsruhe, Germany). Real-time PCR was performed
using the AbiPrism 7700 Sequence Detector (Applied Bio-
systems) as follows: One initial step at 50°C for 2 minutes
and 95°C for 2 minutes was followed by 40 cycles at 95°C
for 15 seconds and 60°C for 1 minute. Detection of the
dequenched probe, calculation of threshold cycles (Ct val-
ues), and further analysis of these data were performed by
the Sequence Detector software. Relative changes in IL-8
mRNA expression compared to unstimulated control and
normalized to GAPDH were quantified by the 2-ddCt
method.
For detection of both IL-8 splice forms 1 μg of RNA was
used for standard RT-PCR (Applied Biosystems, Darm-
stadt, Germany) with GoTaq DNA polymerase (Promega,
Mannheim, Germany). The following sequences were per-
formed for PCR: 94°C for 10 min (1 cycle); 95°C for 30
s, 59°C for 30 s, and 72°C for 1 min (with variable num-
bers of cycles); extension phase at 72°C for 7 min. Num-
bers of cycles: GAPDH, 24; IL-8, as indicated. SequencesBMC Cancer 2008, 8:265 http://www.biomedcentral.com/1471-2407/8/265
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of the primers and length of resulting amplicons: IL-8 (F)
5'-atgacttccaagctggcc gtggct-3'; IL-8 (R1): 5'-ttatgaattct-
cagccctcttcaaaaa-3' (detects the dominat form of IL-8),
299 bp; IL-8 (R2): 5'-ccctgttttcagggacctctgc-3' (detects the
minor/rare form of IL-8, this form is denoted as IL-8 vari-
ant in the figures in the results, 294 bp; GAPDH (F): 5'-
accacagtccatgccatcac-3', GAPDH (R): 5'-tccaccaccctgttgct-
gta-3', 452 bp.
10 μg of total RNA were used for RPA analysis of IL-8
mRNA expression. DNA probes were cloned into the tran-
scription vector pBluescript II KS (+) (Stratagene, Heidel-
berg, Germany). After linearization, an antisense
transcript was synthesized in vitro by T7 RNA polymerase
and [α-32P]UTP (800 Ci/mmol). RNA samples were
hybridized at 42°C overnight with 50,000 c.p.m. of the
labeled antisense transcript. Hybrids were digested by
RNase A and RNase T1 (Roche) for 1 hour at 30°C. Under
these conditions every single mismatch was recognized by
the RNases. Protected fragments were separated on 5%
(w/v) polyacrylamide/8 M urea gels and analyzed using a
PhosphoImager device (Fuji, Straubenhardt, Germany).
Individual expression of IL-8 was evaluated on the basis of
the GAPDH housekeeping gene expression and is shown
as n-fold induction. The cloned cDNA probes for detec-
tion of IL-8 and GAPDH correspond to nucleotides (nt)
16–270 and nt 961–1071 of the published sequences
(hIL-8, NM000584.2; hGAPDH, AC M33197).
Detection of inhibitor of κBα(IκBα), cyclooxygenase-2 
(COX-2), IL-8, and β-actin by Western blot analysis
A549 cells were harvested using lysis buffer (150 mM
NaCl, 1 mM CaCl2, 25 mM TrisCl, pH 7.4, 1% Triton-X-
100, supplemented with protease inhibitor cocktail
(Roche Diagnostics, Mannheim, Germany) and DTT,
Na3VO4, PMSF (each 1 mM) and NaF (20 mM)). 50 μg of
total protein/lane were used. Antibodies and SDS-PAGE
conditions: IκBα, 12% SDS-PAGE, polyclonal antibody
(Santa Cruz Biotechnology); COX-2, 10% SDS-PAGE,
monoclonal antibody (Santa Cruz Biotechnology); IL-8,
18% SDS-PAGE, monoclonal antibody (R&D Systems,
Wiesbaden, Germany); for detection of β-actin (mono-
clonal antibody, Sigma) blots were stripped and rep-
robed. For detection of intracellular IL-8, cells were
incubated with Brefeldin A (BfA) at 10 μg/ml (Sigma,
Hamburg, Germany) in order to suppress the cellular
secretory machinery. In those experiments all conditions
were adjusted to a final concentration of 0.05% DMSO in
order to control for the BfA vehicle.
Statistics
Data are shown as mean ± SD and are presented as pg/ml,
ng/ml, or as fold-induction compared to unstimulated
control. Data were analyzed by unpaired Student's t test
on raw data using Sigma PLOT/STAT (Jandel Scientific).
Results
IFNγ impairs release of IL-8 from IL-1β-stimulated A549 
cells
In accord with previous reports [20] we observed strong
induction of IL-8 secretion by A549 cells under the influ-
ence of IL-1β. A saturation range was reached at an IL-1β
concentration of 1 ng/ml (Figure 1A). IL-8 release could
not be further enhanced, even by increasing the dose of IL-
1β to 25 ng/ml or 50 ng/ml, respectively (data not
shown). In the present study we sought to investigate a
potential regulatory role of IFNγ concerning IL-1β-
induced IL-8 in A549 cells. All subsequent experiments
were performed by using high saturating IL-1β concentra-
tions (≥ 1 ng/ml) in order to ensure complete pro-inflam-
matory activation of those cells and thus to set a high
hurdle for modulation of IL-8 production by anti-inflam-
matory intervention. As shown in Figure 1B, coincubation
with IFNγ significantly impaired release of IL-8 from IL-
1β-stimulated A549 cells during a 24 h incubation period.
IFNγ as a single stimulus was unable to mediate IL-8
release by A549 cells (data not shown). Figure 1C demon-
strates that preincubation of A549 cells with IFNγ for 16 h
even more enhanced this inhibitory action of IFNγ on IL-
1β-induced IL-8 release. Notably, the modulatory func-
tion of IFNγ was already detectable after a 4 h incubation
period with IL-1β (Figure 1C).
The modulatory function of IFNγ on IL-8 secretion is not 
associated with changes in cellular IL-8 mRNA or protein 
expression
Since reduction of IL-8 mRNA expression is an appealing
potential mechanism responsible for the inhibitory IFNγ
action observed herein, real-time PCR analysis for IL-8
gene expression was performed (Figure 2A). Notably,
despite thorough investigation we were unable to detect
significant changes of IL-8 mRNA levels under the influ-
ence of IFNγ. In this same set of experiments IL-1β-
induced IL-8 protein release (10 h stimulation period)
was inhibited by IFNγ by 52.3% ± 5.0% compared to IL-
1β alone (set as 100%). A lack of an IFNγ effect on the
level of IL-8 mRNA expression was also obtained using
RNase protection assay as an alternative method for quan-
tification of mRNA populations (Figure 2B). Although
both splice variants of IL-8 (Swiss-Prot/TrEMBL, http://
www.expasy.org/cgi-bin/get-all-varsplic.pl?P10145)
would be recognized by the ELISA used herein, we sought
to investigate whether IL-8 splicing is affected by coincu-
bation of A549 cells with IFNγ. For that purpose standard
PCR analysis was performed using primers pairs that spe-
cifically discriminate between the different C-termini of
both IL-8 forms. Figure 2C demonstrates that we were
unable to detect the minor/rare splice form of IL-8
(denoted as IL-8 variant) in A549 cells, irrespective of the
presence or absence of IFNγ.BMC Cancer 2008, 8:265 http://www.biomedcentral.com/1471-2407/8/265
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IFNγ modulates release of IL-8 by IL-1β-stimulated A549 cells Figure 1
IFNγ modulates release of IL-8 by IL-1β-stimulated A549 cells.(A) A549 cells were incubated as unstimulated control, 
or stimulated with the indicated concentrations of IL-1β. After 24 h, cell-free supernatants were assayed for IL-8 protein con-
tent by ELISA analysis. Data are expressed as mean IL-8 concentrations ± SD (n = 4). **p < 0.01 compared with untreated con-
trol. (B) A549 cells were incubated as unstimulated control, stimulated with IL-1β (25 ng/ml), or with IL-1β (25 ng/ml) in 
combination with the indicated concentrations of IFNγ. After 24 h, cell-free supernatants were assayed for IL-8 content by 
ELISA analysis. Data are expressed as mean IL-8 concentrations ± SD (n = 8). **p < 0.01 compared with IL-1β alone. (C) A549 
cells were incubated as unstimulated control or were stimulated with IL-1β (25 ng/ml). Where indicated, A549 cells were pre-
incubated for 16 h with IFNγ at different concentrations (ranging from 3.1 ng/ml up to 25 ng/ml). IL-1β was added directly 
thereafter to the cultures without further washing. After the indicated time periods with or without IL-1β stimulation, cell-free 
supernatants were assayed for IL-8 content by ELISA analysis. Data are expressed as mean IL-8 concentrations ± SD (n = 7). 
**p < 0.01 (for IFNγ at 3.1 ng/ml) compared with IL-1β alone.
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In order to further characterize the mechanism of IFNγ
action on IL-1β-induced IL-8 production, secretion of the
cytokine was blocked by coincubation with BfA. Western
blot analysis under those condition clearly demonstrated
that translation of IL-8 mRNA into protein is not affected
by IFNγ (Figure 2D).
IFNγ is not a general inhibitor of IL-1β action on A549 cells
In order to investigate whether IFNγ should be regarded as
a general inhibitor of IL-1β action on A549 cells, COX-2
(Figure 3A) and IL-6 (Figure 3B) were investigated as addi-
tional prototypic IL-1β-inducible proteins. Interestingly,
Western blot and ELISA analysis revealed that expression/
IFNγ is unable to modulate IL-8 mRNA and protein expression under the influence of IL-1β Figure 2
IFNγ is unable to modulate IL-8 mRNA and protein expression under the influence of IL-1β. A549 cells were incu-
bated as unstimulated control, or stimulated with IL-1β (1 ng/ml). Where indicated, A549 cells were preincubated for 16 h 
with IFNγ at 20 ng/ml. IL-1β was added directly thereafter to the cultures without further washing. After 10 h, IL-1β-induced 
IL-8 mRNA accumulation was evaluated by realtime PCR analysis (A) and RPA (B), respectively. IL-8 mRNA expression was 
normalized to that of GAPDH. (A) Data are expressed as fold-induction compared to unstimulated control ± S.D. (n = 3). IL-
8 protein levels in cell-free culture supernatants of those same cultures were determined by ELISA analysis (see results sec-
tion). (B) One representative of three independently performed RPA analyses is shown. (C) RNA populations were analyzed 
by standard PCR using primers pairs that specifically detect the two IL-8 splice variants. The minor/rare splice form of IL-8 is 
denoted as 'IL-8 variant'. (D) A549 cells were incubated as unstimulated control, or stimulated with IL-1β (1 ng/ml). Where 
indicated, A549 cells were preincubated for 16 h with IFNγ at 20 ng/ml. Furthermore, 1 h before stimulation with IL-1β, BfA 
(10 μg/ml) was added to all cultures in order to block the cellular secretory machinery. After 8 h of incubation with IL-1β, cells 
were harvested and cellular IL-8 protein expression was assessed by Western blot analysis. One representative of three inde-
pendently performed experiments is shown.BMC Cancer 2008, 8:265 http://www.biomedcentral.com/1471-2407/8/265
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release of neither parameter was significantly affected by
IFNγ in the context of IL-1β-activated A549 cells. Those
data concur with the further observation that IFNγ was
likewise unable to modulate degradation of IκBα in
response to IL-1β, indicating that IFNγ left activation of
nuclear factor-κB (NF-κB) under those conditions unaf-
fected (Figure 3C). In addition to that, experiments using
conditioned media from IFNγ-stimulated A549 cells also
excluded the possibility that IFNγ mediates production of
an 'IL-8 binding protein' that might have impaired IL-8
detection by ELISA (data not shown).
Discussion
Impaired production of Th1-like cytokines and/or
enhanced expression of Th2-like cytokines and IL-10 has
been associated with tumor progression in a variety of
Analysis of IL-6 release, COX-2 expression, and IκB degradation reveals that IFNγ can not be regarded as a general inhibitor of  IL-1β action on A549 cells Figure 3
Analysis of IL-6 release, COX-2 expression, and IκB degradation reveals that IFNγ can not be regarded as a 
general inhibitor of IL-1β action on A549 cells.(A) A549 cells were incubated as unstimulated control, or stimulated 
with IL-1β (12.5 ng/ml). Where indicated, A549 cells were preincubated for 16 h with IFNγ at 20 ng/ml. IL-1β was added 
directly thereafter to the cultures without further washing. After 24 h, cell-lysates were assayed for COX-2 expression by 
Western blot analysis. One representative of three independently performed experiments evaluating COX-2 expression is 
shown. (B) A549 cells were incubated as unstimulated control, or stimulated with IL-1β (12.5 ng/ml). Where indicated, A549 
cells were preincubated for 16 h with either IFNγ at 12.5 ng/ml (without later addition of IL-1β) or with the indicated concen-
trations of IFNγ in combination with IL-1β (12.5 ng/ml). IL-1β was added directly thereafter to the cultures without further 
washing. After 24 h, cell-free supernatants were assayed for IL-6 secretion by ELISA. Data are expressed as mean IL-6 concen-
trations ± SD (n = 3). **p < 0.01 compared with untreated control. (C) A549 cells were incubated as unstimulated control or 
stimulated with IL-1β (12.5 ng/ml). Where indicated, A549 cells were preincubated for 16 h with IFNγ at 20 ng/ml. IL-1β was 
added directly thereafter to the cultures without further washing. After 15 min or 30 min, cells were harvested and homoge-
nates were evaluated for IκBα-protein by Western blot analysis. One representative for three independently performed 
experiments is shown.BMC Cancer 2008, 8:265 http://www.biomedcentral.com/1471-2407/8/265
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malignancies, including lung cancer [21-23]. Modulation
of angiogenesis appears to be a prime mechanism by
which anti-cancer immunity restrains growth of solid
tumors [24]. Specifically, production of the IFNγ-induci-
ble angiostatic non-ELR+chemokines CXCL-9 (MIG),
CXCL-10 (IP-10), and CXCL-11 (I-TAC) is of key rele-
vance in this context [6]. Accordingly, production of
CXCL-9 and CXCL-10 has been associated with tumor-
suppression in animal models of NSCLC [25,26]. In the
present study we demonstrate for the first time that IFNγ
has the capability to significantly inhibit secretion of the
pro-angiogenic chemokine IL-8 by A549 NSCLC cells. It is
important to bear in mind that IL-8 not only is a mediator
of angiogenesis but is obviously a crucial chemoattractant
for neutrophils [27]. In this context it is of interest that
lung carcinogenesis driven by inflammation has been
associated with influx of neutrophils into the airway com-
partment [28]. The current observation concurs with dis-
tinct anti-inflammatory properties of immunoregulatory
IFNγ [29] that include modulation of IL-8 secretion as pre-
viously noted for other human cell types including mono-
cytes/macrophages [30], synoviocytes [31], and
melanoma cells [32]. Effects of IFNγ on IL-8 were not of
unspecific nature but displayed discrete specificity since
IL-1β-induced expression/secretion of COX-2 and IL-6
were left unaffected. Analysis of cellular IL-8 mRNA and
protein expression furthermore revealed that effects of
IFNγ on IL-8 release by A549 cells do not affect IL-8 pro-
duction but are obviously mediated by an unforeseen
mechanism that targets the process of secretion and war-
rants further investigation.
Generally speaking, clinical trials investigating the thera-
peutic potential of IFNγ in cancer had a disappointing
outcome [33]. However, one phase II clinical study sug-
gests that a subgroup of NSCLC patients may benefit from
therapeutic intravenous application of IFNγ in combina-
tion with chemotherapy. This trend observed did not
reach statistical significance, possibly due to the fact that
numbers of patients included in that trial were limited (26
for chemotherapy alone versus 27 for chemotherapy plus
IFNγ). Moreover, an increased incidence of hematological
toxicity was evident in the study arm undergoing intrave-
neous IFNγ treatment [34]. In the context of lung pathol-
ogy application by aerosol might be of considerable
advantage with regard to the therapeutic potential of IFNγ.
Delivery of IFNγ by inhalation represents a route of
administration that achieves high local concentrations at
the lung along with reduced systemic toxicity in human
beings [35]. In fact, this strategy proved promising in a
murine model of lung cancer [16]. Moreover, inhalation
of IFNγ has already been suggested for the treatment of
tuberculosis and appears to show clinical efficacy [18,19].
In light of the current data and regarding previously pub-
lished information delineating the tumorsuppressive
potential of IFNγ it is tempting to speculate that inhaled
IFNγ may pharmacologically differ from systemically
applied and may indeed act as an immunostimulatory/-
regulatory adjuvant with the potential to provide thera-
peutic benefit.
Conclusion
Taken together, data presented herein suggest that the Th1
signature cytokine IFNγ may not only be able to modulate
angiogenesis in the NSCLC microenvironment by increas-
ing the production of anti-angiogenic non-ELR+ chemok-
ines. Concurrently, IFNγ clearly has the potential to
suppress the production of pro-angiogenic IL-8 by A549
NSCLC carcinoma cells. This observation might be of
translational relevance as clinical studies identified IL-8 as
being a factor that is strongly associated with reduced sur-
vival of NSCLC patients [9,10].
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